Aligos Therapeutics Files 8-K on Financials
Ticker: ALGS · Form: 8-K · Filed: Aug 6, 2025 · CIK: 1799448
| Field | Detail |
|---|---|
| Company | Aligos Therapeutics, Inc. (ALGS) |
| Form Type | 8-K |
| Filed Date | Aug 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: ALGS
TL;DR
ALGS filed an 8-K on Aug 6, 2025, for financial reporting.
AI Summary
Aligos Therapeutics, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing signifies a routine update on Aligos Therapeutics' financial status and operational results, which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial reporting and does not disclose any new material risks or adverse events.
Key Players & Entities
- Aligos Therapeutics, Inc. (company) — Registrant
- August 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K filing?
The provided text indicates the filing pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail specific figures.
What is the exact date of the earliest event reported in this filing?
The earliest event reported is August 6, 2025.
What is the principal executive office address for Aligos Therapeutics, Inc.?
The principal executive offices are located at One Corporate Dr., 2nd Floor, South San Francisco, California 94080.
What is the SIC code for Aligos Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What is the Commission File Number for Aligos Therapeutics, Inc.?
The Commission File Number is 001-39617.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 regarding Aligos Therapeutics, Inc. (ALGS).